Search Results for:
-
Other News To Note
Harvard and Evotec will work together to identify and optimize small-molecule inhibitors for the targets based on technologies licensed from HarvardBioWorld Today | Friday, May 17, 2013 -
Ambit Cuts Price, Ups Shares; $65M IPO to Fund Quizartinib
In its S-1 filing, Esperion, of Plymouth, Mich., is looking to raise $70 million to boost work on its oral small molecule for lowering low-density lipoprotein cholesterol (LDL-C...An oral small molecule, ETC-1001 is designed as an alternative to statin therapy such as Lipitor (atorvastatin, PfizerBy Jennifer Boggs | BioWorld Today | Friday, May 17, 2013 -
Committee Looks for the Bright Line in Compounding
While those local compounders still exist, the lack of oversight has led to the emergence of a new industry that compounds both small-molecule drugs and biologics in bulk and markets them throughout the countryBio Perspectives | Wednesday, May 15, 2013 -
Other News To Note
Ablynx NV, of Ghent, Belgium, initiated preclinical development of next-generation anti-IgE Nanobody ALX-0962 in severe allergic asthma. ALX-0962 consists of a potent anti-IgE Nanobody with a dual mode of action – the ability to bind with high affinity to IgE while also displacing receptor-bound IgE – together with a serum albumin binding Nanobody for in vivo plasma half-life extension. BioAlliance Pharma SA, of Paris, reported the International Independent Board of Experts' data and safetyBioWorld International | Wednesday, May 15, 2013 -
Fungal Protein Points Way to New Breast Cancer Treatments
What is more, they have already found a small molecule that blocks the receptor, and they have crystallized the binding pocket, which should make it possible to design or find other small molecules that can be used as drugs to inhibit the growth of breast cancer cells...The small molecule that de Boer and his colleagues have used to block the estrogen receptor is called fusicoccin, which is a product of the fungus Phomopsis amygdaliBy Sharon Kingman | BioWorld International | Wednesday, May 15, 2013 -
Astellas Axes OSI, Perseid Units, Cuts Jobs in Japan
sales force, a pipeline of small molecules and early stage discovery capabilitiesBy Marie Powers | BioWorld Today | Wednesday, May 15, 2013 -
Other News To Note
ProQinase GmbH, of Freiburg, Germany, and Mercachem BV, of Nijmegen, the Netherlands, received a €2.5 million (US$3.24 million) grant from the European Union's Eurostars program to support their joint efforts to establish and expand a small molecule drug discovery platform that will combine biological and pharmacological assay systems with chemical space libraries targeted against most prominent epigenetic enzyme familiesBioWorld Today | Tuesday, May 14, 2013 -
American Association for Cancer Research: April 2013
small-molecule chemotherapeutic Recurrent glioblastoma multiforme or progressive secondary brain tumor Phase I/II data showed that it did not reach dose-limiting toxicity, and no drug-related adverse effects were detected among patients who failed other available therapies 4/11/13 Exelixis Inc. (South San Francisco) Cometriq Cabozantinib Castration-resistant prostate cancer Bone metastases showed a 67% rate of bone scan response and other clinical signs of effect 4/12/13 Onconova TherapeuticsBioWorld Insight | Monday, May 13, 2013 -
Phase II Clinical Trials Update: April 2013
Phase IIa data showed evidence of efficacy, with five patients reported as being in remission at the final (six-month) follow-up 4/23/13 CANCER Axelar AB (Stockholm, Sweden) AXL1717 Small-molecule IGF-1 receptor inhibitor Non-small-cell lung cancer Phase II data showed it is effective 4/3/13 BioInvent International AB (Lund, Sweden) BI-505 A human antibody that binds to the ICAM-1 adhesion protein Smoldering multiple myeloma The first patient has been treated in a Phase II study 4/23/13BioWorld Insight | Monday, May 13, 2013 -
Diagnostics Rapidly Evolving, Ideal Companions in Drug R&D
The company is developing companion imaging diagnostics and small molecule drug conjugates (SMDCs) for personalized therapy in cancer and other diseases...and may respond to ibrutinib, an oral, small-molecule inhibitor of Bruton tyrosine kinaseBy Peter Winter | BioWorld Insight | Monday, May 13, 2013 -
Phase III Clinical Trials Update: April 2013
small-molecule inhibitor of Bruton tyrosine kinase Chronic lymphocytic leukemia/small lymphocytic lymphoma Has enrolled its fifth patient in a Phase III monotherapy trial using ibrutinib vsBioWorld Insight | Monday, May 13, 2013 -
Array Expanding Capabilities, Runs First Phase III Trial
In addition to internally discovered drugs that it has partnered, Array also offers drug discovery services, leveraging its proprietary lead generation library of 300,000 small molecules to identify modulators of targets a partner might be interested inBy Brian Orelli | BioWorld Insight | Monday, May 13, 2013 -
Week in Review
Nimbus Discovery LLC signed a co-development agreement with Shire plc focused on small molecule treatments for lysosomal storage disordersBioWorld Insight | Monday, May 13, 2013 -
Committee Looks for the Bright Line in Compounding
While those local compounders still exist, the lack of oversight has led to the emergence of a new industry that compounds both small-molecule drugs and biologics in bulk and markets them throughout the countryBy Mari Serebrov | BioWorld Today | Friday, May 10, 2013 -
Oncobiologics, Zhejiang Huahai Form Global Alliance
Huahai is a small-molecule, medium-sized generic company with over $500 million in revenue...Huahai was the first Chinese company to distribute a small molecule product in the U.SBy Catherine Shaffer | BioWorld Today | Thursday, May 9, 2013 -
Other News To Note
Nimbus Discovery LLC, of Cambridge, Mass., signed a co-development agreement with Shire plc, of Dublin, Ireland, focused on small molecule treatments for lysosomal storage disordersBioWorld Today | Thursday, May 9, 2013 -
Galapagos Lands $71M from Stoked U.S. Investors
Galapagos is developing small molecules to address a major mutation, with four separate programs in drug discoveryBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013 -
Expanding Redx Inks Cancer Alliance with Pharmascience
Murray said it was decided to in-license the CSR-1R inhibitor to enable Liverpool, UK-based Redx to build further value around the team of 111 researchers it has recruited since the formation of the oncology division in November 2011, to carry out drug discovery work around the company's small-molecule platform technology...It transpires that AstraZeneca has been working on the development of the BioHub center to house tenant companies since late 2012, some three months at least before it wasBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013 -
Other News To Note
ADX71441 is an oral small molecule, with potential for once-daily dosing...Dipraglurant is an oral, small-molecule allosteric modulator designed to inhibit mGlu5, a Class C G protein-coupled receptorBioWorld International | Wednesday, May 8, 2013 -
Tufts Study: More Cancer Drugs Succeeding in the Clinic
However, small molecules dominated as a percentage of cancer drugs entering clinical trials, representing 73 percent of compounds during 1993 to 1998 and 71 percent in 1999 to 2004...Small-molecule drugs also had a higher overall success rate, at 14.3 percent, than biologics, at 11 .5 percent, over the 12-year study period – a finding mirrored in other drug categories, DiMasi saidBy Marie Powers | BioWorld Today | Wednesday, May 8, 2013
Category
Current Filters
- xsmall molecule
Related Keywords
Categories
- x BioWorld Today (4775)
- x BioWorld Insight (901)
- x BioWorld International (854)
- x State of the Industry Report (117)
- x BioWorld Genomics Review (112)
- x Bio Perspectives (102)
- x BioWorld Snapshots (35)
- x Top 25 Drug Report (19)
- x Biotech Innovations (19)
- x Market-Leading Biotech Drugs (6)
- x RNAi Report (3)
- x Featured (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.